TBTommaso Bucci

Tommaso Bucci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tommaso Bucci has a total of 348 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CO046 | BLEEDING RISK FACTOR–BASED PHENOTYPES AND THEIR ASSOCIATION WITH MORTALITY AND HEMORRHAGIC OUTCOMES IN ATRIAL FIBRILLATION

    by Tommaso Bucci

    Background and aims. In patients with atrial fibrillation (AF), multiple bleeding risk factors are well established. However, whether these factors cluster into distinct clinical phenotypes and how these phenotypes relate to mortality and bleeding outcomes remains unclear.Methods. This prospective observational study included consecutive patients with AF who initiated non-vitamin K oral anticoagulant (NOAC) therapy between 2013 and 2018. Bleeding risk factors were defined a priori based on clinical relevance and literature evidence and included age >75 years, previous bleeding, chronic kidney disease (CKD), cirrhosis, systolic blood pressure >140 mmHg (uncontrolled hypertension), concomitant antiplatelet therapy, NSAID use, and alcohol abuse. These variables were collected at baseline, and patients were stratified into a low-risk group (0–1 risk factors) and a higher-risk group (≥2 risk factors). Unsupervised clustering using latent class analysis (LCA) was applied to the higher-risk group to identify distinct bleeding risk phenotypes. Associations with primary outcomes (all-cause mortality and composite bleeding) and secondary outcomes (major bleeding and clinically relevant non-major bleeding [CRNMB] according to the ISTH definition) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models.Results. Overall, 1,039 patients were included (age 75.2±9.6 years, 56.8% female), of whom 316 (30.4%) were classified as low risk. Among the 723 (69.6%) patients in the higher-risk group, four distinct clusters were identified. Cluster 1 represented a frail phenotype, characterized by a high burden of bleeding risk factors, including advanced age, previous bleeding, CKD, and high fall risk. Cluster 2 was defined by alcohol abuse. Cluster 3 was characterized by a high prevalence of NSAID and antiplatelet use. Cluster 4 was characterized by uncontrolled hypertension. After a median follow-up of 1,539 days (IQR 1,124–1,863), 336 (32.3%) deaths and 277 (26.6%) composite bleeding events occurred. Compared with the low-risk group, all clusters showed an increased risk of all-cause mortality, with the highest risk observed in Cluster 1 (HR 2.99, 95% CI 2.17–4.12) (Figure 1). For composite bleeding, Cluster 1 (HR 1.87, 95% CI 1.30–2.69) and Cluster 4 (HR 1.49, 95% CI 1.06–2.10) were significantly associated with increased risk, whereas the association for Cluster 2 was borderline (HR 1.39, 95% CI 0.97–1.99) and not significant for Cluster 3 (Figure 1). Among secondary outcomes, Cluster 1 remained associated with an increased risk of both major bleeding (HR 2.03, 95% CI 1.04–3.95) and CRNMB (HR 1.79, 95% CI 1.18–2.72) (Figure 1). Clusters 2 and 4 showed an increased risk of CRNMB (HR 1.49, 95% CI 1.00-2.22 and HR 1.62, 95% CI 1.11-2.36, respectively), whereas associations for Cluster 3 were not significant (Figure 1).Conclusions. Bleeding risk factors cluster into distinct clinical phenotypes associated with different risks of mortality and hemorrhagic outcomes.

  • Open Access

    SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

    by Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip

    Background and Aim: Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, including adults with Fabry disease and eGFR ≥ 20 mL/min/1.73 m 2 , excluding Type 1 diabetes. Patients were stratified by SGLT2 inhibitor exposure. The primary outcome was a composite of all‐cause death, acute myocardial infarction and acute or acute‐on‐chronic heart failure at 2 and 5 years; secondary outcomes included individual components and progression to advanced kidney disease. Patients with prior non‐fatal outcomes were excluded from the respective analyses. Propensity score matching (1:1) and Cox proportional hazards models were used. Sensitivity analyses included alternative follow‐up periods, restriction to Fabry disease diagnosed from 2013 onwards and a stricter Fabry disease definition requiring ≥ 2 diagnoses; subgroup analyses were performed by sex and age. Results: Among 14 940 FD patients, 1028 (6.9%) had recorded exposure to SGLT2 inhibitors (mean age: 65.5 ± 12.0 years; 53.0% male), who were older and had a higher comorbidity burden and worse baseline renal profile than non‐exposed patients. After PSM, 732 patients per group (exposed and non‐exposed patients) were available for analysis. At 2 years, SGLT2i exposure was associated with a lower risk of the composite outcome (HR 0.61; 95% CI 0.38–0.97) and all‐cause death (HR 0.56; 95% CI 0.33–0.95). At 5 years, results were consistent for the composite outcome (HR 0.56; 95% CI 0.39–0.79) and all‐cause death (HR 0.62; 95% CI 0.42–0.93), with reduced myocardial infarction risk (HR 0.53; 95% CI 0.30–0.90). Conclusions: In a large real‐world FD cohort, SGLT2i exposure was associated with lower cardiovascular risk and mortality, supporting further prospective investigation.

  • Open Access

    Adverse Events and ABC Pathway Adherence Across AF Clinical Phenotypes

    by Tommaso Bucci, Giulio Francesco Romiti, Marta Mantovani, Davide Antonio Mei, Alena Shantsila, Wee-Siong Teo, Hyung-Wook Park, Wataru Shimizu, Hung-Fat Tse, Marco Proietti, et al.


  • Open Access

    Early recurrence of atrial tachyarrhythmia after catheter ablation and its associations with clinical outcomes, atrial fibrillation burden, and blanking period duration: a post hoc analysis of the CABANA trial

    by Hongyu Liu, Runhui Hu, Wenhui Li, Eva Soler-Espejo, Tommaso Bucci, Yang Liu, Manlin Zhao, Tianshu Gu, Weiguo Fan, Bi Huang, et al.

    Aims: Early recurrence of atrial tachyarrhythmia (ERAT) after catheter ablation for atrial fibrillation (AF) is common, yet its prognostic significance and implications for the duration of the blanking period remain uncertain. We aimed to evaluate the association between ERAT and post-ablation clinical outcomes, late arrhythmia recurrence, and AF burden, and to explore the optimal duration of the blanking period. Methods and results: This post hoc analysis included 811 patients from the CABANA trial who underwent catheter ablation and had trial-specific electrocardiographic monitoring data available. ERAT was defined as any episode of AF, atrial flutter, or atrial tachycardia lasting >30 s within the 90-day blanking period. The primary outcome was a composite of all-cause mortality, disabling stroke, serious bleeding, or cardiac arrest. Secondary outcomes included cardiovascular hospitalization and late atrial tachyarrhythmia recurrence. During a median 4 years (IQR 2.5–5.2) follow-up, ERAT occurred in 567 patients (69.9%). Patients with ERAT had higher risks of cardiovascular hospitalization [adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI) 1.07–1.71] and of the composite outcome of all-cause mortality or cardiovascular hospitalization (aHR 1.33, 95% CI 1.07–1.66), but no increased risk of the primary composite outcome. ERAT was independently associated with late atrial tachyarrhythmia recurrence (aHR 1.35, 95% CI 1.07–1.71). Prognostic relevance varied by timing, with the strongest association observed for ERAT occurring between 60 and 90 days after ablation (aHR 1.80, 95% CI 1.16–2.79). Receiver operating characteristic analysis identified 58 days as the optimal threshold for predicting late arrhythmia recurrence (AUC 0.727). Conclusion: ERAT was associated with higher risks of cardiovascular hospitalization and late atrial tachyarrhythmia recurrence in a time-dependent manner, supporting a shorter blanking period to better identify patients at risk of adverse rhythm outcomes.


  • Open Access

    Impact of Anaemia on Management and Outcomes in Patients With Atrial Fibrillation: Insights From European and Asian Cohorts

    by Andrea Galeazzo Rigutini, Tommaso Bucci, Amir Askarinejad, Enrico Tartaglia, Michele Rossi, Cecilia Becattini, Giuseppe Boriani, Hung‐Fat Tse, Tze‐Fan Chao, Gregory Y. H. Lip

    Background: Anaemia is a common comorbidity in patients with atrial fibrillation (AF) receiving oral anticoagulants (OACs). While its relationship with bleeding is well established, the prothrombotic role and ethnic variations remain unclear. Methods: We analysed two large prospective AF registries from Europe (EORP‐AF) and East Asia (APHRS‐AF). Patients were classified by anaemia status at enrolment. Logistic regression assessed clinical correlates and treatment patterns, while multivariable Cox models and propensity score matching (PSM) evaluated outcomes. Restricted cubic spline analyses explored the haemoglobin–risk relationship across ethnic groups. The primary outcome was a composite of all‐cause death and major adverse cardiovascular events (MACE); secondary outcomes included individual components and major bleeding (MB). Results: Among 10,857 patients with AF (mean age 69 ± 11 years, 40.0% women), 3372 (31.0%) had anaemia, which clustered with multimorbidity and frailty. Anaemic patients were less likely to receive OACs (OR 0.67, 95% CI 0.58–0.78) and rhythm‐control (OR 0.91, 95% CI 0.81–1.02). Anaemia was independently associated with higher risk of the composite outcome (HR 1.54, 95% CI 1.34–1.78), all‐cause death (HR 1.81, 95% CI 1.51–2.15), MACE (HR 1.39, 95% CI 1.16–1.66), CV death (HR 1.90, 95% CI 1.43–2.54) and MB (HR 1.79, 95% CI 1.31–2.46) consistent also after PSM. Risk increased progressively with anaemia severity, particularly below 10 g/dL. Associations were consistent across Asian and European cohorts. Conclusion: Anaemia identifies a vulnerable AF phenotype associated with excess mortality, adverse cardiovascular outcomes and increased bleeding risk, which remains frequently undertreated. Risk rises with anaemia severity, and although biological effects appear consistent across ethnicities, treatment disparities persist. Anaemia should refine, not restrict, therapy within integrated AF care.

  • Open Access

    In Vitro Ocular Cytotoxicity of BEE Venom in ARPE-19, NTM5, HCET, and HCEC-12 Cell Lines

    by Emine Kubra Bilir, Hidayet Tutun, Sedat Sevin, Şeyda Kıvrak, Tommaso Bucci, Rachel Williams

    Bee venom (BV) is a complex natural secretion of Apis mellifera with documented anti-inflammatory, antimicrobial, and anticancer properties. Despite its therapeutic potential, safety concerns remain due to its strong cytotoxic effects, particularly in sensitive tissues such as the eye. In this study, we evaluated the composition and ocular cytotoxicity of purified BV obtained from the Muğla ecotype of Apis mellifera anatoliaca . High-performance liquid chromatography with variable wavelength detection (HPLC-VWD) confirmed the presence of three principal components; melittin (71.08 ± 0.33%), phospholipase A₂ (12.98 ± 0.27%), and apamin (3.02 ± 0.25%) at retention times consistent with reference standards. Cytotoxicity was assessed in four human ocular cell lines: ARPE-19 (retinal pigment epithelium), NTM5 (trabecular meshwork), HCE-T (corneal epithelium), and HCEC-12 (corneal endothelium), using MTT viability assays and live/dead staining over 24 h and 48 h. BV exerted strong, dose and time dependent cytotoxic effects across all cell lines, with ARPE-19 and NTM5 cells exhibiting the highest sensitivity. IC₅₀ values were 22.36 µg/mL (24 h) and 12.55 µg/mL (48 h) in ARPE-19, and 20.78 µg/mL (24 h) and 13.07 µg/mL (48 h) in NTM5 cells. By contrast, HCEC-12 and HCE-T cells displayed moderate sensitivity, with IC₅₀ values between 29 and 34 µg/mL. These findings highlight tissue-specific differences in BV susceptibility. While BV may offer therapeutic promise, its narrow safety margin in ocular cells underscores the importance of controlled delivery strategies to minimize toxicity. This study provides foundational data for evaluating the ocular safety profile of BV and informs future translational applications.


  • Open Access

    Long-term prognosis in Takotsubo syndrome compared to heart failure: observations from a global federated research network

    by Enrico Tartaglia, Muath Alobaida, Tommaso Bucci, Michele Rossi, Amir Askarinejad, Ho Man Lam, Mert Kaskal, Andrea Galeazzo Rigutini, Giuseppe Boriani, Gregory Y H Lip

    Introduction: To compare long-term outcomes of patients with Takotsubo syndrome (TTS) and heart failure (HF). Methods: This retrospective observational study used the TriNetX global federated research network. Adult patients (≥18 years) discharged with a diagnosis of TTS (ICD-10-CM I51.81) or HF (I50.x) between 2018 and 2022 were identified. Primary outcomes were 3-year risk of all-cause death, major adverse cardiovascular events (MACE; myocardial infarction or ischaemic stroke), and acute HF. Secondary outcomes included myocardial infarction, ischaemic stroke, ventricular arrhythmias (ventricular tachycardia), malignant arrhythmias (ventricular fibrillation or cardiac arrest), and new-onset atrial fibrillation (AF). Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) before and after 1:1 propensity score matching (PSM). Subgroup analyses were performed by HF phenotype, age (≥65 vs <65 years), and mental health status. Results: The study included 2240 patients with TTS (mean age 62.6 ± 17.3 years; 73.7% female) and 265 564 patients with HF (69.3 ± 14.7 years; 45.8% female). After PSM, TTS was associated with a lower risk of acute HF (HR 0.622, 95% CI 0.539–0.717), ventricular arrhythmias (HR 0.637, 95% CI 0.441–0.919), malignant arrhythmias (HR 0.656, 95% CI 0.571–0.754), new-onset AF (HR 0.672, 95% CI 0.517–0.875), and myocardial infarction (HR 0.818, 95% CI 0.687–0.974), with no significant differences in the remaining outcomes. Differences were greater when TTS was compared with heart failure with reduced ejection fraction. Conclusions: TTS is associated with lower risk of adverse events than HF. Further research is needed on mental health in its pathogenesis and prognosis.


  • Open Access

    Prognostic Impact of New‐Onset Atrial Fibrillation After Cardiac Arrest: Observations From a Federated Research Network

    by Enrico Tartaglia, Tommaso Bucci, Amir Askarinejad, Michele Rossi, Muath Alobaida, Steven Ho Man Lam, Mert Kaskal, Andrea Galeazzo Rigutini, Shir Lynn Lim, Giuseppe Boriani, et al.

    Background: Data on adverse events in patients developing atrial fibrillation (AF) after cardiac arrest (CA) are limited. Methods: Retrospective analysis using the TriNetX network. Adults (≥ 18 years) with CA (ICD‐10‐CM I46) from 2014 to 2024 were divided into two cohorts: those with new‐onset AF (I48) within 2 days after CA and those without. Primary outcome was the 1‐year risk of a composite of all‐cause death, stroke, acute myocardial infarction (AMI), and recurrent CA. Secondary outcomes were the individual components. Cox regression provided hazard ratios (HRs) and 95% confidence intervals (CIs) before and after 1:1 propensity score matching (PSM). Sensitivity analyses stratified follow‐up into early (3–33 days) and late (34–367 days) phases; subgroups included age, sex, hypertension, diabetes, heart failure, and shockable rhythms. Results: We identified 1221 patients with post–CA AF (mean age 65 ± 14.9 years; 33.8% female) and 149 222 without AF (57.9 ± 17.6 years; 39.3% female). Before PSM, AF patients were older and had greater cardiovascular burden. After PSM post–CA AF was associated with higher risk of the composite outcome (HR 1.25, 95% CI 1.13–1.38), AMI (HR 1.59, 95% CI 1.30–1.95), recurrent CA (HR 1.48, 95% CI 1.30–1.70), and a non‐significant trend toward increased stroke risk, which was greater during the early phase post‐CA. Female patients showed stronger association between post–CA AF and stroke (p for interaction = 0.04). Conclusion: Post–CA AF is associated with an increased risk of adverse events, including AMI and recurrent CA. Stroke risk was higher during the early post‐resuscitation phase and among female patients.

  • Open Access

    Physical activity and risk of adverse events in atrial fibrillation: evidence from European and Asian cohorts

    by Michele Rossi, Tommaso Bucci, Enrico Tartaglia, Amir Askarinejad, Steven Ho Man Lam, Andrea Galeazzo Rigutini, Claudio Ferri, Giuseppe Boriani, Hung-Fat Tse, Tze-Fan Chao, et al.

    Aims: To evaluate differences in clinical characteristics and outcomes based on physical activity levels in patients with atrial fibrillation (AF), comparing Europeans and Asians. Methods and results: Post-hoc analysis of two prospective registries from Europe and the Asia-Pacific. Patients were classified as inactive (no exercise or <3 h/week) or active (≥3 h/week). The primary outcome was a composite of all-cause death and major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death, MACE, major bleeding, individual MACE components. Cox model estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes. Subgroup analyses were performed by clinically relevant variables and enrolment setting. Of 13 126 participants (69 ± 12 years; 39% female), 3639 (28%) were physically active and 9487 (72%) physically inactive. Across both groups, Asians had lower odds of obesity, symptomatic AF and heart failure, but higher odds of cardiovascular risk factors than Europeans. After a median follow-up of 514 days, physically active AF patients had a lower risk of composite outcome (HR 0.66, 95%CI 0.56–0.78), all-cause death (HR 0.52, 95%CI 0.42–0.65), MACE (HR 0.80, 95%CI 0.65–0.99), cardiovascular death (HR 0.60, 95%CI 0.42–0.86), with no significant differences between Europeans and Asians (pinteraction for composite outcome = 0.298). The risk of the composite outcome decreased progressively with increasing levels of physical activity, with no significant differences between Europeans and Asians (pinteraction = 0.845). Conclusion: In patients with AF, self-reported physical activity is associated with a lower risk of adverse events, consistently across Europe and Asia. Physical activity may represent a component of a lower-risk clinical profile in AF.